[Asia Economy Reporter Lee Gwan-joo] Curatis announced on the 4th that it visited Indonesia on the 1st and discussed with the director and staff of the Indonesian Food and Drug Authority (BPOM) the clinical trial progress of the next-generation mRNA COVID-19 vaccine 'QTP104' booster shot in Indonesia.
They also presented on vaccine platform technology and local business plans. The company explained that there was high interest in securing mRNA vaccines locally in Indonesia, and interest in the tuberculosis vaccine 'QTP101' for adolescents and adults under development was also reaffirmed.
QTP104 is the first next-generation mRNA vaccine (self-replicating, self-amplifying mRNA or replicon RNA) developed domestically, having received approval for phase 1 clinical trials from the Ministry of Food and Drug Safety in July last year. Compared to existing mRNA vaccines, it can induce a strong immune response with a smaller dose, and since it does not contain PEG components, it has almost no allergic reactions, drawing attention for its safety.
Jo Gwan-gu, CEO of Curatis, said, “Through this visit to Indonesia's BPOM, we reaffirmed the willingness for development cooperation and support between the two countries, and we hope that the clinical trials of the next-generation mRNA COVID-19 vaccine in Indonesia will proceed swiftly with BPOM's cooperation.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
